10 June 2013

MedLumics appoints Dr. Wolfgang Reim as Independent Director

Madrid, 10th June 2013. MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of the industry expert Wolfgang Reim as Independent Director for its board.

“Wolfgang’s experience in the process of creation, development and commercialization of medical technology, his global vision of the market of medical imaging and his proven strategic skills will contribute to turn the technology innovation developed by MedLumics into clinical value”, said Eduardo Margallo, President and co founder.

Dr. Reim studied Mathematics and Physics at ETH Zürich, Switzerland, obtaining his PhD in experimental physics at the same institution. He brings a valuable experience to MedLumics as a result of the broad range of executive responsibilities held at leading companies in the medical technology industry. He was CEO at Dräger Medical AG & Co. KG and a member of the Board of Directors at Drägerwerk AG for 7 years. Previously, he was president for the Ultrasound Division at Siemens Healthcare, based in the US, and was holding top executive positions in areas such as magnetic resonance imaging, mammography, urology, lithotripsy, surgery, portable X rays and accessories before. At the beginning of his career, this expert worked at the R&D centers of IBM and Siemens. Currently, Wolfgang Reim is a member of the Board of Directors at Carl Zeiss Meditec AG, GN Store Nord A/S, Ondal Medical Systems and Elekta AB.

Dr. Wolfgang Reim has kept up to date with the development of the company from the start of its operations through a close contact with its founders and investors and as a member of the Scientific Advisory Board of MedLumics. His role as independent director will focus on strategic decisions related to product portfolio development, corporate growth and business opportunities.

According to Wolfgang Reim, “MedLumics is building a singular non-invasive imaging platform based on integrated optics with the potential to transform clinical practice in important areas as cardiology, dermatology or surgery. It is a pleasure for me to accept the position ofIndependent Director and help the company become a recognized player in the medical technology industry. I am convinced that together we are going to improve the standard of care for millions of patients worldwide, providing them with better healthcare systems by making more efficient and effective medical solutions available.”

About MedLumics
Founded in 2009, MedLumics is a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology. Its proprietary platform technology integrates optical and electrical components in a compact microchip-based OCT system that can produce dynamic, real-time, high-resolution diagnostic images that allow physicians to perform a non-invasive optical “digital biopsy” of tissues. MedLumics received a 3.5 million Euro/4.7 million USD Series A financing from joint investors Ysios Capital Partners and “la Caixa” (through Caixa Capital Risc) in November 2011. For more information, visit www.medlumics.com